idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
E m b a r g o e d until:
Wednesday, August 3, 2005, 18 hours London Time/13 00 US Eastern Time
Cells under stress apparently possess two different safety systems that prevent them from turning into cancer cells. Apoptosis is one such system, which enables damaged cells to literally commit suicide in order to protect the organism as a whole. The second protection program stops the cell cycle, and - although the cells stay alive - they are prevented from further dividing a behavior that would lead to malignant growth. Evidence suggesting the existence of this second system was found a few years ago in the culture dish. Now, using animal models, cancer researchers from the Charité University Medicine Berlin and the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch in Germany have been able to confirm this second program termed senescene (Latin: senex = "old age") and they could show that this program is capable of blocking lymphoma development. The work of Melanie Braig under the guidance of Charité- and MDC-based principal investigator Prof. Clemens A. Schmitt has now been published online in Nature* (doi:10.1038/nature03841).
An enzyme, which the researchers refer to as Suv39h1, plays an important role in mediating senescence in white blood cells (lymphocytes). The enzyme is activated when the oncogene ras turns on genes in lymphocytes, and prevents them from undergoing uncontrolled cell growth and, subsequent conversion into cancer cells. Hence, lack of Suv39h1 can pave the way for the development of a very aggressive lymphoma. Interestingly, the availability of the apoptotic program is not disengaged by cellular senescence. Thus the tumor can still be treated with chemotherapy that engages apoptotic programs to kill cancerous cells.
*Oncogene-induced senescence as an initial barrier in lymphoma development
Melanie Braig1, Soyoung Lee1, Christoph Loddenkemper2, Cornelia Rudolph3, Antoine H.F.M. Peters4,5, Brigitte Schlegelberger3, Harald Stein2, Bernd Dörken1,6, Thomas Jenuwein5 & Clemens A. Schmitt1,6
1Charité - Universitätsmedizin Berlin/Haematology-Oncology, 13353 Berlin, Germany. 2Charité - Universitätsmedizin Berlin /Department of Pathology, 12200 Berlin, Germany. 3Institute of Cell and Molecular Pathology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. 4Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland. 5Research Institute of Molecular Pathology, 1030 Vienna, Austria. 6Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany.
For further information:
Prof. Dr. med. Clemens Schmitt, M.D.
Charité - Universitätsmedizin Berlin (CVK), and MDC
Augustenburger Platz 1
13353 Berlin, Germany
Tel. +49-30-450 553 687
Fax +49-30-450 553 986
Mobile +49-163-76 96 864
e-mail clemens.schmitt@charite.de
Press and Public Affairs of the MDC
Barbara Bachtler
Robert-Rössle-Str. 10
13125 Berlin, Germany
Phone: +49/30/9406-38 96
Fax.: +49/30/9406-38 33
e-mail: bachtler@mdc-berlin.de
http://www.mdc-berlin.de
Criteria of this press release:
Biology, Information technology, Medicine, Nutrition / healthcare / nursing
transregional, national
Research results, Scientific Publications
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
